Vasant Prakash Gandhi
Chief Executive Officer at Molecular Decisions Strategy LLC
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Robert Bradway | M | 61 | 18 years | |
| Robert Eckert | M | 69 | 21 years | |
| David Reese | M | 61 | 19 years | |
| Esteban Santos | M | 56 | 17 years | |
| Matthew Busch | M | 50 | 20 years | |
| Derek Miller | M | - | 21 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Edward V. Fritzky | M | 73 |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 11 years |
| David W. Beier | M | 75 | 10 years | |
| Patrick Soon-Shiong | M | 71 |
Abraxis BioScience, Inc.
 Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 3 years |
| Michael Kelly | M | 67 | 14 years | |
| Lonnie Moulder | M | 66 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 1 years |
| Paul Eisenberg | M | - | 14 years | |
| Douglas Williams | M | 66 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 15 years |
| Leonard Schaeffer | M | 78 | 9 years | |
| Daniel J. Burge | M | 62 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 3 years |
| John Smither | M | 71 | 6 years | |
| Jin Long Chen | M | 61 | 4 years | |
| Jean-Francois Gimonet | M | - |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 3 years |
| Cynthia Flowers | F | 64 | 5 years | |
| Diana McKenzie | F | 59 | 12 years | |
| William Ashton | M | 73 | 16 years | |
| Wayne A. Davey | M | - |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 3 years |
| Gregory L. Tewalt | M | - | - | |
| Michael Severino | M | 58 | 10 years | |
| Craig Shepherd | M | - | 7 years | |
| Cynthia Patton | F | 62 | 15 years | |
| Willard Dere | M | 70 | 11 years | |
| Susan Lundeen Smuck | F | 57 | 12 years | |
| Erin Lavelle | F | 46 | 15 years | |
| Nathan Hardy | M | 48 | 10 years | |
| Paul J. Carter | M | - |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 3 years |
| Sean B. W. Martin | M | 61 | - | |
| Bruce Wendel | M | 70 |
Abraxis BioScience, Inc.
Abraxis BioScience, Inc. Pharmaceuticals: MajorHealth Technology Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA. | 4 years |
| Anna Richo | F | 63 | 9 years | |
| Dominique Monnet | M | 65 | 11 years | |
| Peggy Phillips | F | 70 |
Immunex Corp.
Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | 6 years |
| Frank Herringer | M | 81 | 15 years | |
| David J. Scott | M | 71 | - | |
| Patricia Cary Sueltz | F | 71 | 2 years | |
| Timothy Martin | M | 55 | 3 years | |
| Krishnan Mahesh /davita/ | - | - | 5 years | |
| Deepak Nath | M | - | - | |
| Yi Ning Zhao | M | 53 | 5 years | |
| Charles R. Bradley | M | - | 5 years | |
| John F. Weidenbruch | M | 63 | 10 years | |
| Timothy Powers | M | 58 | 5 years | |
| Diane Parks | F | 71 | 7 years | |
| Kirsten Detrick | F | 59 | 9 years | |
| Joanne Viney | M | 58 | 9 years | |
| Sunita Zalani | M | - | 8 years | |
| Catherine Stehman-Breen | M | 61 | 12 years | |
| Brian Kotzin | M | 74 | 11 years | |
| Eliot Charles | M | 62 | 3 years | |
| Andrew Partridge | M | 55 | 10 years | |
| Edward A. Imbrogno | M | 60 | 7 years | |
| Ann Miller | M | 66 | 5 years | |
| Marlene Haffner | M | 83 | 2 years | |
| Kenneth Lock | M | 50 | 6 years | |
| David Weinreich | M | - | 7 years | |
| Feng Ye | M | 57 | 12 years | |
| Paul Romness | M | 57 | 3 years | |
| Roland Wandeler | M | 51 | - | |
| Sesha Neervannan | M | 56 | 8 years | |
| Thomas-Christian Mix | M | 57 | 12 years | |
| Christophe Quéva | M | 57 | 5 years | |
| Qin Xia | F | 56 | 14 years | |
| Margrit Schwarz | M | 60 | 7 years | |
| Jeffrey Wiezorek | M | 52 | 8 years | |
| Steven J. Ruhl | M | - | - | |
| Michael Wittekind | M | 69 | 4 years | |
| Peter K. Watler | M | 62 | 12 years | |
| T. Tyler Ellison | M | - | 1 years | |
| Nick Abbott | M | - | 10 years | |
| Bradley J. Maroni | M | 71 | 6 years | |
| Terry Rosen | M | 65 | 9 years | |
| Carl LeBel | M | 65 | 10 years | |
| Frederick A. Fletcher | M | - | 10 years | |
| Warren Wayne Myers | M | 62 | 10 years | |
| Eric Grinstead | M | 66 | 7 years | |
| Giuseppe Giorgini | M | - | - | |
| Timothy Hoey | M | 65 | - | |
| Susan R. Lundeen-Smuck | F | 58 | 9 years | |
| Stuart Tross | M | 57 | 10 years | |
| Dung Thai | M | - | - | |
| John G. Adair | M | - | 6 years | |
| James G. Stout | M | 58 | 4 years | |
| Helen Torley | M | 61 | 8 years | |
| Joshua J. Ofman | M | 60 | 16 years | |
| Vimal Srivastava | M | 58 | 3 years | |
| Oranee T. Daniels | M | - | - | |
| Richard Davies | M | 62 | 9 years | |
| Andrew Knudten | M | - | 13 years | |
| Maureen P. Brogan | F | 62 | 3 years | |
| Majed Kheir | M | 46 | 6 years | |
| Timothy McNamara | M | 67 | 3 years | |
| Jesse Seton McGreivy | M | 54 | 6 years | |
| Doug Farrar | M | 59 | 7 years | |
| Marc D. Better | M | 68 | 5 years | |
| Wen-Tse Tseng | M | - | 5 years | |
| Mike Nanfito | M | - | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Vasant Prakash Gandhi
- Personal Network